RecruitingPhase 4NCT07308574

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome

Sponsor

Alexion Pharmaceuticals, Inc.

Enrollment

20 participants

Start Date

Dec 19, 2025

Study Type

INTERVENTIONAL

Conditions

Atypical Hemolytic Uremic Syndrome aHUS

Summary

The primary objective of this study is to assess the platelet count response to ravulizumab in participants clinically diagnosed as atypical hemolytic uremic syndrome (aHUS).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ravulizumab for people with atypical hemolytic uremic syndrome and ahus. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRavulizumab

Participants will receive ravulizumab via IV infusion.

Locations(12)

Research Site

Bunkyō City, Japan

Research Site

Hirakata-shi, Japan

Research Site

Iruma-Gun, Japan

Research Site

Kyoto, Japan

Research Site

Matsumoto-shi, Japan

Research Site

Miyazaki, Japan

Research Site

Nagoya, Japan

Research Site

Nara, Japan

Research Site

Nerima-ku, Japan

Research Site

Sapporo, Japan

Research Site

Shinjuku-ku, Japan

Research Site

Tsu, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07308574

Related Trials

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

NCT057951409 locations

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

NCT0593521531 locations

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

NCT072185368 locations

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

NCT059967311 location

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

NCT058052021 location